This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
B-RAF with PLX4032
From Proteopedia
(Difference between revisions)
| (35 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
| - | == | + | ==B-RAF with PLX4032== |
| - | + | PLX4032 is a newly synthesized drug that is being used to treat malignant melanoma with a specific mutation. The mutation is B-RAF^(V600E). This drug is highly selective for this mutation and will not bind to wild type B-RAF. | |
| - | + | ||
| - | + | ||
| - | Replace the PDB id (use lowercase!) after the STRUCTURE_ and after PDB= to load | ||
| - | and display another structure. | ||
| - | <applet load='3og7' size=' | + | <applet load='3og7' size='400' color='white' frame='true' align='right' caption='BRAF kinase domain complex with PLX4032 (PDB code [[3og7]])' /> |
| + | <scene name='B-RAF_with_PLX4032/Plx_4032_only/2'>PLX 4032</scene><br> | ||
| + | <scene name='B-RAF_with_PLX4032/Atp/2'>ATP</scene><br> | ||
| + | <scene name='B-RAF_with_PLX4032/Wild-type_b-raf/2'>Wild-Type B-RAF</scene> <br> | ||
| + | <scene name='B-RAF_with_PLX4032/Mutated_v600e/2'>V600E Mutation</scene> <br> | ||
| + | <scene name='B-RAF_with_PLX4032/H-bond/4'>H-Bond Interaction Asp594 and PLX4032</scene><br> | ||
| + | <scene name='B-RAF_with_PLX4032/Superposition3og71uwh/4'>Superposition overview</scene> <br> | ||
| + | <scene name='B-RAF_with_PLX4032/Superposition3og71uwh/5'>Superposition close up</scene> <br> | ||
| + | <scene name='B-RAF_with_PLX4032/Superposition3og71uwh/2'>Superposition active site</scene> <br> | ||
Current revision
B-RAF with PLX4032
PLX4032 is a newly synthesized drug that is being used to treat malignant melanoma with a specific mutation. The mutation is B-RAF^(V600E). This drug is highly selective for this mutation and will not bind to wild type B-RAF.
|
